Share on facebook
Share on twitter
Share on linkedin
Share on telegram
Share on whatsapp

Lipid Nanoparticles A Key Component Of COVID Vaccines Stick To Your Organs Found Pfizer’s Own Study

Share on facebook
Share on twitter
Share on telegram
Share on email
Share on print

In information obtained through a Freedom of Information Act lawsuit filed by Judicial Watch, Pfizer’s own study revealed that lipid nanoparticles, a key component of their COVID vaccines, stick to your organs, especially the liver, adrenal glands, spleen, and ovaries.

Judicial Watch today announced that it had received 466 pages of records (pdf below) from the Department of Health and Human Services (HHS) relating to biodistribution studies and related data for the COVID-19 vaccines, which show that lipid nanoparticles (LNPs), a key component of the vaccines developed by Pfizer/BioNTech, were found outside the injection site, primarily in the liver, adrenal glands, spleen, and ovaries of test animals, 8 to 48 hours after injection.

LNPs are used as a delivery mechanism in Pfizer/BioNTech’s mRNA-based COVID vaccine. Acuitas Therapeutics LNP technology is used in COMIRNATY, the Pfizer/BioNTech COVID-19 vaccine, according to a press release issued by Pfizer on January 10, 2022.

The records were obtained through a Freedom of Information Act (FOIA) lawsuit (Judicial Watch v. U.S. Department of Health and Human Services (No. 1:21-cv-02418)) filed by Judicial Watch after the Food and Drug Administration, the Centers for Disease Control and Prevention, and the National Institute for Allergy and Infectious Disease failed to respond to a June 8, 2021, FOIA request for:

Access to biodistribution studies and related data for the Pfizer, Moderna, and Johnson & Johnson vaccines used to treat and/or prevent SARS-CoV-2 and/or COVID-19.

In a section titled “Safety Pharmacology,” the report notes, “No safety pharmacology studies were conducted with BNT162b2 [the BioNTech vaccine] as they are not considered necessary for the development of vaccines according to the WHO guideline (WHO, 2005).”

When lipid nanoparticles (LNPs) “with a comparable composition” to those used in in the Pfizer COVID vaccine were injected into rats, “total recovery (% of injected dose) of LNP outside the injection site was greatest in the liver and was much less in the spleen, adrenal glands, and ovaries,” according to this Pfizer report.

Source: GreatGameIndia, Judicial Watch v HHS FDA Pfizer BioNTech Vaccine prod 3 02418 pgs 3-36 FOIA Doc

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Get in Touch!

Purpose of your Contact
Where can i reach you?
What would you like to discuss?
[crypto-donation-box]

Are you intending to visit the Lorphic marketing agency?